October/November #167 : Editor's Letter - by Regan Hofmann

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

From Mice Into Men

The Doctor Is In




At the End of Your Rope?

A Slippery Slope?

Senior Strength




POZ Q&A: Jeffrey Crowley

Standing Against Stigma

The Stigma Index

ADAP Update

Get Your Game On

It’s Everyone’s Business

Pozarazzi




Editor's Letter

Letters

No Hate



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

October / November 2010


Editor's Letter

by Regan Hofmann

RIP Rx

On the cover of this magazine nearly 10 years ago, POZ asked, “Whatever Became of the Cure?” I remember, as a reader then, thinking it was a damn good question. In the flurry of congratulatory activity around effective antiretroviral (ARV) therapy, there was too little focus on the end game: eradicating the virus itself.


Don’t get me wrong. I am thrilled ARVs prolonged my life. But, I also wish I didn’t have to take them. Since protease inhibitors debuted in 1996, a great deal of money and energy has been applied to improving the treatment formulations. Newer, more effective, easier to tolerate drugs have played a huge role in compliance, which has led to less drug resistance and better health for people with HIV.

But it is troubling that we haven’t spent as much time, energy and money developing a way to kiss the drugs good-bye forever—a delicious thought suggested by the picture of an empty medicine cabinet on POZ’s cover a decade ago.

In that issue, legendary AIDS treatment activist Martin Delaney, founder of Project Inform, prophesied that we would see a functional cure—full viral suppression without ARV therapy—“by 2010, at the very latest.” Tragically, we lost Marty in January 2009, and we still don’t have a cure. In a bittersweet twist, the National Institutes of Health (NIH) named a new research grant after Marty. The grant—$8.5 million a year for five years—will support the search for a functional cure.

The answer to how we find a cure is largely financial. As you will see in our feature story on page 20, while a new grant like this shows a commitment to AIDS research, we aren’t spending anywhere near what the experts say we must to find a cure soon.

Ten years ago, Marty asked, “So should we just give up? Should we tell people to settle for a lifetime of pill-induced misery?” (The answer, of course, is no!)

Today, that question is doubly vexing, because for many people around the world, a lifetime of pills isn’t even an option. The price of keeping tens of millions of people on ARV therapy for the rest of their lives is not a check anyone is prepared, or able, to pick up. We can’t get the drugs to everyone, and as we explain in “At the End of Your Rope,” there is also another factor—a growing number of people who are running out of treatment options with no new answers readily in sight.

In light of our most dire need for a cure, I ask those of us lucky enough to still be here—thanks, in large part, to treatment activists like Marty—to pick up where he and other advocates left off. Let’s refuse to let another decade go by without getting to say RIP to our prescriptions for HIV.

Because if we don’t find the cure soon, we will bury tens of millions of people. And as Anthony Fauci, MD, the director of the National Institute of Allergy and Infectious Diseases said when he first saw the millions who needed treatment but weren’t getting it, “This is just something that as human beings we can’t accept.”

I would like to dedicate this issue of POZ to the memory of Martin Delaney and all who hoped they would live to see the cure, and did not. May they rest in peace. And may we not rest until we help usher in their dream of the end of AIDS.

Search: Cure, ARV, inhibitors, Regan Hofmann, NIH, Martin Delaney, Project Inform


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dave41
    Bethany
    Oklahoma


    Sin_Grinder
    Reno
    Nevada


    OahuAJ
    Turlock
    California


    jacob2608
    Panama City Beach
    Florida
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.